← Russell 3000 cross-section

AURA Aura Biosciences, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$805m
Revenue TTM
$7m
Net income TTM
$-131m
Free cash flow
$-103m
Composite score
28.8
Sector rank
#2153

Valuation

P / E
EV / EBITDA
EV / sales
107.5
FCF yield
-12.84%
Earnings yield vs 10-yr
-21.01pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-1,910.9%
EBITDA margin
-1,997.3%
ROE
-41.6%
ROIC
-55.8%
Revenue growth
-9.4%

Insider activity, last 90 days

Net open-market
$-0.08m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Furthermore, such training increases our costs to generate sales associated with any such product. Further, as a result of increased hybrid work, a significant number of our employees and partners are working remotely, which increases the risk of a cybersecurity incident or data breach or other data and cybersecurity issues. For example, under the GDPR, entities that violate the GDPR can face fines of up to the greater of 20 million euros (£17.5 million under UK GDPR) or 4% of their worldwide annual turnover, or revenue. …Aura Biosciences, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →